Nateglinide

Nateglinide, a D-phenylalanine derivative, is an orally active and short-acting insulinotropic agent and a DPP IV inhibitor. Nateglinide inhibits ATP-sensitive K+ channels in pancreatic β-cells. Nateglinide is used for the treatment of type 2 (non-insulin-dependent) diabetes mellitus[1][2].

Product Specifications

CAS Number

[105816-04-4]

Product Name Alternative

A4166; Senaglinide

UNSPSC

12352005

Hazard Statement

H302, H361

Target

Dipeptidyl Peptidase; Potassium Channel

Type

Reference compound

Related Pathways

Membrane Transporter/Ion Channel; Metabolic Enzyme/Protease

Applications

Neuroscience-Neuromodulation

Field of Research

Metabolic Disease

Assay Protocol

https://www.medchemexpress.com/Nateglinide.html

Purity

99.95

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

O=C(O)[C@@H](CC1=CC=CC=C1)NC([C@H]2CC[C@H](C(C)C)CC2)=O

Molecular Formula

C19H27NO3

Molecular Weight

317.42

Precautions

H302, H361

References & Citations

[1]Christopher J. Dunn, et al. Nateglinide. OFILE Drugs 2000 Sep: 60 (3) : 6.|[2]Shiling Hu, et al. Interaction of nateglinide with KATP channel in h-cells underlies its unique insulinotropic action. European Journal of Pharmacology. 442 (2002) 163-171.|[3]Jian Luo, et al. Evaluating insulin secretagogues in a humanized mouse model with functional human islets. Metabolism. 2013 Jan;62 (1) :90-9.|[4]Duffy NA, et al. Effects of antidiabetic drugs on dipeptidyl peptidase IV activity: nateglinide is an inhibitor of DPP IV and augments the antidiabetic activity of glucagon-like peptide-1. Eur J Pharmacol. 2007 Jul 30;568 (1-3) :278-86.